TSVT
2seventy bio, Inc. [TSVT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TSVT Stock Summary
Top 10 Correlated Stocks
TSVT
In the News
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as originally planned.
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer therapy.
2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
3 Biotech Stocks With Key Catalysts Coming in December
Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Short squeeze alert for October 18th: 2 stocks that could soar
In stock trading, shorting is seen as a high-risk, high-reward strategy. This approach involves borrowing stocks, selling them, and betting on their price dropping to make a profit.
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Upcoming announcements from the U.S. Food and Drug Administration could cause several biotech stocks to rocket higher. Alnylam is expecting a decision regarding a progressive heart condition that could lead to billions in additional annual sales.
2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal
2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.
2seventy bio to lay off 40% of workforce
2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.
TSVT Financial details
TSVT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.34 | 1.9 | 10.65 | 2.32 | 2.57 | |
| Net income per share | -8.58 | -13.88 | -5.93 | -11.75 | -7.13 | |
| Operating cash flow per share | -6.28 | -8.93 | -2.91 | -8.81 | -6.65 | |
| Free cash flow per share | -8.46 | -11.5 | -3.87 | -9.64 | -7.3 | |
| Cash per share | 0 | -5.74 | -5.48 | 11.28 | 7.47 | |
| Book value per share | 0 | 1.88 | 3.2 | 15.31 | 8.71 | |
| Tangible book value per share | 0 | 0.91 | 2.4 | 14.38 | 8.17 | |
| Share holders equity per share | 0 | 1.88 | 3.2 | 15.31 | 8.71 | |
| Interest debt per share | 0 | 5.74 | 5.48 | 12.01 | 7.34 | |
| Market cap | 320.67M | 320.67M | 320.67M | 602.28M | 333.92M | |
| Enterprise value | 0 | 587.82M | 575.87M | 754.08M | 533.06M | |
| P/E ratio | -1.61 | -0.99 | -2.32 | -2.18 | -1.31 | |
| Price to sales ratio | 5.88 | 7.24 | 1.29 | 11.05 | 3.65 | |
| POCF ratio | -2.19 | -1.54 | -4.73 | -2.91 | -1.41 | |
| PFCF ratio | -1.63 | -1.2 | -3.56 | -2.66 | -1.28 | |
| P/B Ratio | 0 | 7.34 | 4.3 | 1.67 | 1.08 | |
| PTB ratio | 0 | 7.34 | 4.3 | 1.67 | 1.08 | |
| EV to sales | 0 | 13.27 | 2.32 | 13.83 | 5.83 | |
| Enterprise value over EBITDA | 0 | -1.82 | -5.08 | -2.41 | -2.12 | |
| EV to operating cash flow | 0 | -2.83 | -8.49 | -3.64 | -2.25 | |
| EV to free cash flow | 0 | -2.2 | -6.39 | -3.33 | -2.05 | |
| Earnings yield | -0.62 | -1.01 | -0.43 | -0.46 | -0.76 | |
| Free cash flow yield | -0.61 | -0.83 | -0.28 | -0.38 | -0.78 | |
| Debt to equity | 0 | 3.06 | 1.71 | 0.78 | 0.87 | |
| Debt to assets | 0 | 0.42 | 0.41 | 0.37 | 0.41 | |
| Net debt to EBITDA | 0 | -0.83 | -2.25 | -0.48 | -0.79 | |
| Current ratio | 0 | 0.2 | 0.33 | 2.96 | 3.77 | |
| Interest coverage | -13.14 | 0 | 0 | 0 | 30.88 | |
| Income quality | 0.73 | 0.65 | 0.56 | 0.71 | 0.93 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 3.67 | 6.72 | 1.19 | 4.8 | 2.72 | |
| Intangibles to total assets | 0 | 0.07 | 0.06 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0.35 | 0.29 | 0.33 | 0.09 | 0.1 | |
| Capex to revenue | -0.93 | -1.35 | -0.09 | -0.36 | -0.25 | |
| Capex to depreciation | -3.81 | -4.75 | -1.69 | -1.2 | -1.98 | |
| Stock based compensation to revenue | 0.75 | 1.4 | 0.25 | 1 | 0.45 | |
| Graham number | 0 | 24.21 | 20.68 | 63.64 | 37.39 | |
| ROIC | 0 | -1.1 | -0.5 | -0.32 | -0.31 | |
| Return on tangible assets | 0 | -1.11 | -0.47 | -0.37 | -0.4 | |
| Graham Net | 0 | -17.14 | -12.62 | -7.62 | -1.61 | |
| Working capital | 0 | -82.56M | -50.76M | 193.18M | 221.09M | |
| Tangible asset value | 0 | 21.16M | 55.86M | 337.87M | 291.11M | |
| Net current asset value | 0 | -250.42M | -212.89M | -108.29M | -45.32M | |
| Invested capital | 0 | 3.06 | 1.71 | 0.78 | 0.87 | |
| Average receivables | 0 | 0 | 9.06M | 13.84M | 18.98M | |
| Average payables | 0 | 0 | 13.77M | 6.59M | 6.62M | |
| Average inventory | 0 | 0 | 63.8M | 6.74M | -50.24M | |
| Days sales outstanding | 0 | 61.19 | 15.73 | 113.77 | 83.61 | |
| Days payables outstanding | 0 | 2.5K | 483.78 | 174.67 | 100.34 | |
| Days of inventory on hand | 0 | 0 | 8.63K | -3.31K | 189.86 | |
| Receivables turnover | 0 | 5.96 | 23.21 | 3.21 | 4.37 | |
| Payables turnover | 0 | 0.15 | 0.75 | 2.09 | 3.64 | |
| Inventory turnover | 0 | 0 | 0.04 | -0.11 | 1.92 | |
| ROE | 0 | -7.4 | -1.85 | -0.77 | -0.82 | |
| Capex per share | -2.18 | -2.57 | -0.96 | -0.83 | -0.64 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.35 | 1.58K | 0.96 | 0.71 | 0.24 | |
| Net income per share | -1.75 | -649.41 | -0.98 | -0.83 | -1.4 | |
| Operating cash flow per share | -1.58 | -1.56K | -1.13 | -0.64 | -0.42 | |
| Free cash flow per share | -1.93 | -1.65K | -1.27 | -0.72 | -0.47 | |
| Cash per share | 8.38 | 7.47K | 7.82 | 5.55 | 4.9 | |
| Book value per share | 8.38 | 8.71K | 9.23 | 7.21 | 5.99 | |
| Tangible book value per share | 7.87 | 8.17K | 8.79 | 6.84 | 5.85 | |
| Share holders equity per share | 8.38 | 8.71K | 9.23 | 7.21 | 5.99 | |
| Interest debt per share | 7.11 | 7.58K | 6.04 | 5.17 | 5.08 | |
| Market cap | 561.24M | 333.92K | 443.37M | 515.78M | 200.62M | |
| Enterprise value | 707.5M | 199.47M | 516.7M | 683.36M | 370.55M | |
| P/E ratio | -2.08 | 0 | -2.61 | -3.06 | -0.7 | |
| Price to sales ratio | 41.86 | 0.01 | 10.65 | 14.31 | 16.67 | |
| POCF ratio | -9.21 | -0.01 | -9.03 | -15.79 | -9.33 | |
| PFCF ratio | -7.55 | -0.01 | -8.04 | -14.08 | -8.27 | |
| P/B Ratio | 1.74 | 0 | 1.1 | 1.4 | 0.65 | |
| PTB ratio | 1.74 | 0 | 1.1 | 1.4 | 0.65 | |
| EV to sales | 52.77 | 3.55 | 12.41 | 18.96 | 30.79 | |
| Enterprise value over EBITDA | -10.74 | -8.05 | -10.48 | -14.97 | -10.98 | |
| EV to operating cash flow | -11.61 | -3.6 | -10.53 | -20.92 | -17.23 | |
| EV to free cash flow | -9.52 | -3.4 | -9.37 | -18.65 | -15.28 | |
| Earnings yield | -0.12 | -69.31 | -0.1 | -0.08 | -0.36 | |
| Free cash flow yield | -0.13 | -175.63 | -0.12 | -0.07 | -0.12 | |
| Debt to equity | 0.85 | 0.87 | 0.67 | 0.72 | 0.85 | |
| Debt to assets | 0.39 | 0.41 | 0.36 | 0.37 | 0.41 | |
| Net debt to EBITDA | -2.22 | -8.03 | -1.49 | -3.67 | -5.03 | |
| Current ratio | 4.37 | 3.77 | 5.07 | 4.99 | 4.08 | |
| Interest coverage | -61.38 | -1.6K | 11.18 | 0 | 0 | |
| Income quality | 0.9 | 2.4 | 1.04 | 0.78 | 0.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 4.6 | 0.88 | 1.64 | 1.66 | 4.26 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | |
| Capex to operating cash flow | 0.22 | 0.06 | 0.12 | 0.12 | 0.13 | |
| Capex to revenue | -1 | -0.06 | -0.15 | -0.11 | -0.23 | |
| Capex to depreciation | -5.64 | -1.36 | -2.7 | -1.77 | -0.99 | |
| Stock based compensation to revenue | 0.91 | 0.17 | 0.23 | 0.21 | 0.81 | |
| Graham number | 18.15 | 11.28K | 14.25 | 11.57 | 13.73 | |
| ROIC | -0.08 | -0.03 | -0.05 | -0.05 | -0.12 | |
| Return on tangible assets | -0.1 | -0.04 | -0.06 | -0.06 | -0.11 | |
| Graham Net | -1.39 | -1.8K | 0.21 | -0.87 | -1.35 | |
| Working capital | 269.52M | 221.09M | 312.89M | 266.77M | 209.25M | |
| Tangible asset value | 303.65M | 291.11M | 382.14M | 348.49M | 299.65M | |
| Net current asset value | -36.15M | -45.32M | 48.7M | -4.55M | -57.13M | |
| Invested capital | 0.85 | 0.87 | 0.67 | 0.72 | 0.85 | |
| Average receivables | 12.1M | 16.5M | 31.11M | 42.68M | 31.81M | |
| Average payables | 7.33M | 7.6M | 10.3M | 9.84M | 5.79M | |
| Average inventory | 0 | 0 | -20.63M | -42.68M | -22.05M | |
| Days sales outstanding | 80.8 | 33.58 | 89.2 | 110.1 | 145.95 | |
| Days payables outstanding | 1.91K | 42.33 | 280.77 | 125.01 | 96.32 | |
| Days of inventory on hand | 0 | 0 | -864.42 | -878.66 | 0 | |
| Receivables turnover | 1.11 | 2.68 | 1.01 | 0.82 | 0.62 | |
| Payables turnover | 0.05 | 2.13 | 0.32 | 0.72 | 0.93 | |
| Inventory turnover | 0 | 0 | -0.1 | -0.1 | 0 | |
| ROE | -0.21 | -0.07 | -0.11 | -0.11 | -0.23 | |
| Capex per share | -0.35 | -88.84 | -0.14 | -0.08 | -0.05 |
TSVT Frequently Asked Questions
What is 2seventy bio, Inc. stock symbol ?
2seventy bio, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol TSVT
Is 2seventy bio, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26
What is TSVT stock prediction ?
What is 2seventy bio, Inc. stock quote today ?
2seventy bio, Inc. stock price is $3.1 today.
Is 2seventy bio, Inc. stock public?
Yes, 2seventy bio, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.92M
- Market Capitalization 156.91M
- Employee 425
- CEO Mr. Nick Leschly
- Headquarters Cambridge,MA,US
- IPO Date 2021-11-03
-
Website
https://www.2seventybio.com 
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
